The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) ...

On June 12, the Advisory Council on the Implementation of National Pharmacare released its final report which recommends that Canada implement a universa

In March 2023, the Minister of Health announced the National Strategy for Drugs for Rare Diseases, which has as its objective to increase access to, and affordability of, effective drugs for rare diseases...

On December 11, 2017, Health Canada announced a guidance document clarifying the requirements for drug submissions and applications to be processed under the administrative pathway.

The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the...

On April 2, 2020, the Patented Medicine Prices Review Board (PMPRB) published a message from the Chairperson regarding the results of its consultation on the draft Guidelines operationalizing the...

Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview.

On February 6, 2018, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the most recent edition of its series of reports on generic drug pricing.

On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP)...

As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) ...

The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.

The Federal Court of Appeal affirmed that, under the Patent Act, a successful patentee always has a right to its damages, and only it has the right to elect an accounting of profits, subject to the court's discretion.

On January 29, 2020, Bill C-4, which addresses some of the changes required under the Agreement between Canada, the U.S. and Mexico (USMCA), was introduced in the House of...

Earlier this year, the Canadian Patent Office announced that it will increase its official fees on January 1, 2024, in some cases by as much as 36%.

The appellants argued that Apo-Lansoprazole could not and would not have received regulatory approval in April 2007 and Apotex was not entitled to damages.

Therapeutic applications of stem cells are central to the promise of regenerative medicine. An increasing number of stem cell therapies are being approved for clinical use and by some estimates

We are proud to announce a new podcast series with Louis-Pierre Gravelle of B&P in collaboration with ISEQ to demystify and explore the intellectual property (IP)...

On March 30, 2023, the Supreme Court of Canada dismissed Pharmascience's application for leave to appeal (Docket No. 40400) a decision of the Federal Court of Appeal (FCA) upholding the validity...

On November 30, 2018, Global Affairs Canada issued a news release announcing the signing of the Canada-United States-Mexico Agreement (CUSMA or USMCA) ...

On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder.